Costimulation, coinhibition and cancer

Area of Science:

• Immunology
• Cancer Biology
• Oncology

Background:

• The immune system, particularly T lymphocytes, is crucial for anti-cancer defense but is often impaired in cancer patients.
• T lymphocyte activation relies on specific steps, including costimulatory signals from antigen-presenting cells, which can be disrupted in cancer.
• Recent findings reveal that costimulatory signals possess a dual nature, acting as either stimulatory (costimulation) or inhibitory (coinhibition).

Purpose of the Study:

• To review the roles of costimulation and coinhibition as potential therapeutic targets in cancer treatment.
• To provide a framework for understanding immune system dysfunction in cancer.
• To link immune dysfunction in cancer to specific coinhibitory (e.g., PD-1, PD-L1, CTLA-4, BTLA) and costimulatory (e.g., CD28, ICOS, 4-1BB, CD40, OX40, CD27) signaling pathways.

Main Methods:

• Review of existing literature on immune system regulation in cancer.
• Analysis of the interplay between cancer-related immune dysfunction and costimulatory/coinhibitory signaling.
• Development of a model for cancer-related immune dysfunction, drawing parallels with immunoediting.

Main Results:

• Costimulatory and coinhibitory pathways play critical, often opposing, roles in regulating T lymphocyte responses against cancer.
• Dysregulation of these pathways contributes significantly to immune evasion in malignancies.
• Specific molecules like PD-1, PD-L1, CTLA-4, CD28, and ICOS are key players in this complex signaling network.

Conclusions:

• Targeting costimulatory and coinhibitory pathways presents a promising strategy for developing novel cancer immunotherapies.
• Understanding the duality of these signals is essential for optimizing therapeutic interventions.
• The presented model offers a framework for further research into cancer immunoediting and therapeutic strategies, with relevance to renal cell carcinoma.